Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

NCT01393145 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease
COPD

Interventions

DRUG: Combination Fluticasone /Formoterol 12/250 μg
DRUG: Seretide Diskus (salmeterol/fluticasone) 50/250 μg

Sponsor

Ache Laboratorios Farmaceuticos S.A.